Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis

被引：18

作者：

Nagayasu T. ^{[1
,2
]}

Yamayoshi T. ^{[1
]}

Matsumoto K. ^{[1
]}

Ide N. ^{[1
]}

Hashizume S. ^{[1
]}

Nomura M. ^{[1
]}

Muraoka M. ^{[1
]}

Tagawa T. ^{[1
]}

Akamine S. ^{[1
]}

Oka T. ^{[1
]}

机构：

[1] Division of Surgical Oncology, Dept. of Translational Med. Sci., Nagasaki Univ. Grad. Sch. B. S., Nagasaki

[2] Division of Surgical Oncology, Dept. of Translational Med. Sci., Nagasaki Univ. Grad. Sch. B. S., Nagasaki 852-8501

来源：

The Japanese Journal of Thoracic and Cardiovascular Surgery | 2005年 / 53卷 / 1期

关键词：

Myasthenia gravis; Plasmapheresis; Thymectomy;

D O I：

10.1007/s11748-005-1001-y

中图分类号：

学科分类号：

摘要：

Objective: Since 1980, we have performed plasmapheresis before thymectomy for patients with generalized symptoms in order to protect against myasthenic crisis and to improve patient outcomes after thymectomy. The aim of this study was to evaluate an immediate and a long-term results of plasmapheresis before thymectomy for myasthenia gravis, retrospectively. Methods: Between January 1980 and December 1997, 51 patients with Osserman class IIA or IIB symptoms were treated with transsternal thymectomy. Nineteen patients (group 1) were treated with plasmapheresis before thymectomy and 32 patients (group 2) were treated with thymectomy alone. Results: In group 1, the time of plasmapheresis prior to thymectomy was 3.2±1.5. Nine (28.1%) patients in group 2 had crisis within 1 year after thymectomy as compared with only one (5.3%) patient in group 1 had crisis (p=0.049). There was no evidence of crisis within 30 days after thymectomy in group 1 and 5 (15.6%) patients in group 2 (p=0.0724). There was no postoperative death among patients in group 1. Responses to thymectomy in group 1 improved significantly, the improvement and pharmacologic remission rate had increased up to 100% and 79% at 5-7 years after operation, while the improvement and pharmacologic remission rate of group 2 had increased to 81.3% (p=0.0466 vs. group 1) and 50.0% at that time (p=0.0427 vs. group 1). Conclusions: The present study demonstrated that preoperative plasmapheresis may facilitate improved outcomes of patients with myasthenia gravis after thymectomy.

引用

页码：2 / 7

页数：5

共 25 条

[1]

Borel C.O., Management of myasthenic crisis: Continuous anticholinesterase infusions, Crit Care Med, 21, pp. 821-822, (1993)

[2]

Harati Y., Patten B.M., Prednisone use in concurrent autoimmune diseases, Arch Neurol, 36, pp. 103-106, (1979)

[3]

Finn R., Coates P.M., Plasma exchange in myasthenia gravis, Lancet, 1, pp. 190-191, (1977)

[4]

Kornfeld P., Ambinder E.P., Papatestas A.E., Bender A.N., Genkins G., Plasmapheresis in myasthenia gravis: Controlled study, Lancet, 2, (1979)

[5]

Pinching A.J., Peters D.K., Davis J.N., Plasma exchange in myasthenia gravis, Lancet, 1, pp. 428-429, (1977)

[6]

Arsura E.L., Bick A., Brunner N.G., Namba T., Grob D., High-dose intravenous immunoglobulin in the management of myasthenia gravis, Arch Intern Med, 146, pp. 1365-1368, (1986)

[7]

Kamolvarin N., Hemachudha T., Ongpipattanakul B., Phanuphak P., Viddayakorn P., Sueblinvong T., Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis, Acta Neurol Scand, 80, pp. 324-326, (1989)

[8]

Blalock A., Harvey A., Ford F., Lilienthal Jr. J., The treatment of myasthenia gravis by removal of the thymus gland, JAMA, 117, pp. 1529-1531, (1941)

[9]

Monden Y., Uyama T., Nakahara K., Fujii Y., Hashimoto J., Ohno K., Et al., Clinical characteristics and prognosis of myasthenia gravis with other autoimmune diseases, Ann Thorac Surg, 41, pp. 189-192, (1986)

[10]

Papatestas A.E., Genkins G., Kornfeld P., Eisenkraft J.B., Fagerstrom R.P., Pozner J., Et al., Effects of thymectomy in myasthenia gravis, Ann Surg, 206, pp. 79-88, (1987)

← 1 2 3 →